ArticleOrphanet journal of rare diseases2025
Discovery of newborn Wilson disease biomarkers via integrated next-generation sequencing and untargeted metabolomics.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of serum NEAT1 and MALAT1 expression as diagnostic biomarkers in tyrosinemia, a rare metabolic disorder.Orphanet journal of rare diseases · 2026Article
- The gut-liver-kidney-brain axis in Wilson disease: copper speciation-flux and barrier-mediated organ crosstalk.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundWilson disease (WD) is an autosomal recessive disorder caused by variants in the ATP7B gene, leading to copper metabolism dysfunction and multi-organ damage. Early diagnosis is critical for improving clinical outcomes, but current screening methods have limitations. Metabolomics can reveal early metabolic disturbances in disease; however, the metabolic profile of newborns with WD remains unexplored. This study aimed to identify potential metabolic biomarkers for early WD detection through untargeted metabolomic analysis.
methodsDried blood spot (DBS) samples from six genetically confirmed WD positive newborns and 84 healthy controls were analyzed using liquid chromatography-mass spectrometry (LC-MS). Multivariate statistical analysis was employed to identify differentially abundant metabolites. Pathway enrichment analysis and receiver operating characteristic (ROC) curve evaluation were performed to assess diagnostic performance.
resultsA total of 29 significantly altered metabolites (21 upregulated, 8 downregulated) were identified in WD positive newborns, primarily associated with tyrosine metabolism. ROC analysis revealed 11 metabolites with an area under the curve (AUC) > 90%. Additionally, two pairs of isomers also demonstrated exhibited high diagnostic sensitivity and specificity and were closely linked to WD pathogenesis. In positive group, tyrosine metabolism pathway was most significantly affected, as evidenced by increased levels of 3,4-Dihydroxyphenylacetic acid and Homogentisic acid, alongside a decreased level of Gentisaldehyde.
conclusionWD positive newborns exhibit distinct metabolic reprogramming prior to copper accumulation, with tyrosine metabolism dysregulation as a potential early feature. The identified differential metabolites may serve as promising biomarkers for newborn WD screening, providing a foundation for metabolomics-based early diagnostic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.